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Abstract  
We report clinical outcomes of proton therapy in patients with World Health Organization grade 
2 (atypical) meningiomas.  Between 2005 and 2013, 22 patients with atypical meningiomas were 
treated to a median dose of 63 Gy (RBE) using proton therapy, as an adjuvant therapy after 
surgery (n=12) or for recurrence or progression of residual tumor (n=10). Six patients had 
presumed radiation-induced meningiomas, but none had received prior radiotherapy for their 
meningioma.  The median follow-up time after radiation was 39 months (range 7–104) and all 
patients remain alive at last follow-up.  The 5-year estimate of local control was 71.1% (95% CI 
49.3–92.9%).  The 5-year estimate of local control was 87.5% following a radiation dose > 60 
Gy (RBE), compared to 50.0% for ≤ 60 Gy (RBE)  (p=0.038).  The 5-year estimate of neuraxis 
dissemination was 5% (95% CI 0–14.6%) and 6.2% (95% CI 0–18.2%) for metastases outside of 
the central nervous system.  Radiation necrosis was observed in one patient with a history of 
prior cranial irradiation.  Fractionated proton therapy was associated with favorable tumor 
control rates for grade 2 meningiomas. Prospective studies are needed to define the optimal 
radiation dose for high-grade meningiomas. 
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Introduction 
Meningiomas represent approximately 25% of primary brain tumors diagnosed in adults [1].  
The great majority are benign World Health Organization (WHO) grade 1 tumors and long term 
disease control is typically achieved with surgery, radiation, or combination therapy [2-4].  WHO 
grade 2 (atypical) and 3 (anaplastic) meningiomas are uncommon subtypes of meningioma 
which are associated with a higher risk of local recurrence after surgery and radiation [5, 6], and 
a probability of neuraxis dissemination and distant metastases beyond the central nervous system 
(extra-CNS) [7].  While a recent retrospective series suggests that adjuvant radiotherapy is 
associated with improved local control even after gross total resection of atypical meningiomas 
[8], a systematic review of the literature highlights the uncertainties regarding the role of 
radiotherapy in this disease [9]. 
 
The optimal radiation dose for high-grade meningiomas remains unclear [10].  Local control 
with fractionated external beam radiation in conventional doses used for benign meningiomas, 
on the order of 50-54 Gy, is poor [11, 12], and the pattern of failure appears to be primarily in-
field [13], suggesting a rationale for dose escalation or intensification.  However, doses greater 
than 60 Gy have infrequently been used with fractionated X-ray techniques due an increasing 
risk of brain radiation necrosis.  Results of stereotactic radiosurgery for high-grade meningiomas 
have been disappointing [14] and there appears to be a higher risk of marginal tumor failure [15, 
16], although many of these patients receive radiosurgery for salvage after prior fractionated 
external beam radiation. 
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Proton therapy is a modality of radiation therapy distinguished from X-ray radiation by the 
physical property of energy deposition within the target at the Bragg peak.  Proton dosimetry 
exhibits dose deposition to the depth of the target, after which the dose rapidly terminates, 
delivering essentially no radiation beyond the depth of the target.  The absence of exit dose 
minimizes radiation exposure to non-target tissues and can allow for radiation dose escalation 
when indicated [17, 18].  Two prior retrospective reports on combined photon-proton therapy for 
grade 2 and 3 meningiomas suggested a benefit to radiation dose escalation beyond 60 Gy for 
both local tumor control and overall survival [19, 20].  We report our experience using proton 
therapy for atypical WHO grade 2 meningiomas. 
 
Materials and Methods 
Institutional review board approval was obtained for this retrospective review.  Inclusion criteria 
were patients with grade 2 meningiomas who were receiving their initial meningioma-directed 
radiotherapy. Details of the proton beam delivery system have been previously published [21].  
Orthogonal kilovoltage X-ray images were used for daily patient alignment prior to treatment of 
each field, using a robotic patient position with 6 degrees of freedom [22].  Radiotherapy was 
administered exclusively with protons.  Patients were treated with once daily fractionation of 
1.8–2 Gy (RBE).  Proton dose is expressed in Gy (RBE) with a relative biologic effectiveness of 
1.1 compared to megavoltage X-ray therapy. 
 
Treatment planning involved an alpha cradle and thermoplastic mask for immobilization and 
acquisition of a computed tomography (CT) scan with 1 mm slice thickness.  Preoperative and 
postoperative magnetic resonance imaging (MRI) scans were coregistered to delineate the 
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original extent of the tumor, the tumor bed, and any macroscopic residual disease.  The clinical 
target volume was defined as the original tumor bed with an expansion for potential microscopic 
tumor extension, including intraparenchymal brain extension, that varied with anatomic location, 
was anatomically constrained to natural boundaries of spread and typically ranged from 0.5–1 
cm.  Most commonly, a 1 cm expansion was used to treat to 54 Gy (RBE) and then a field 
reduction was made to treat the tumor bed and residual tumor with a 0.5 cm margin.  A 2 mm 
uniform expansion was added for a planning target volume (PTV).  For patients with delayed 
recurrence of tumor after prior surgery, after delivery of an intial 54 Gy (RBE) that encompassed 
the original tumor bed, a field reduction was typically made to encompass the area of recurrent 
disease with similar margins for a boost to the total dose.   
 
Total dose selection was variable over the time period of this study based on the preference of 
different treating physicians. Eight patients received a dose of 60 Gy (RBE) or less. Two patients 
with radiation-induced meningiomas received 54 Gy (RBE) due to concern for cumulative dose 
to the optic apparatus and risk for visual loss. Five received 59.4 Gy (RBE) and one 60 Gy 
(RBE) because the treating physician preferred this dose for atypical meningiomas. Fourteen 
patients received a dose greater than 60 Gy (RBE).  Nine patients received 63 Gy (RBE), one 66 
Gy (RBE), and four 68.4 Gy (RBE). 
 
Follow-up time was calculated from the completion date of radiotherapy.  Information on acute 
and late toxicity was retrospectively gathered from weekly treatment status notes, the treatment 
completion summary, follow-up notes, and correspondence with other physicians.  After 
radiation therapy, patients typically underwent magnetic resonance imaging at 2 months and then 
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every 6 months for tumor surveillance.  Endpoints analyzed were local tumor control, neuraxis 
spread, metastases outside the central nervous system (extra-CNS), and overall survival.  Local 
tumor progression was defined as radiographic enlargement of the residual tumor or 
development of adjacent new areas of tumor, as determined by neuroradiology interpretation of 
follow-up imaging.  Neuraxis spread was diffuse and distant leptomeningeal spread including 
spinal drop metastases.  Five year event estimates were calculated using the Kaplan Meier 
method and 95% confidence intervals (CI) are presented.  The log-rank test was used to perform 
univariate analysis of patient and disease characteristics.  Univariate Cox regression analysis was 
used to assess continuous variables. Statistical analysis was performed with SPSS version 20. 
 
Results 
Between 2005 and 2013, 22 patients with WHO grade 2 meningiomas were treated at the now 
closed Indiana University Health Proton Therapy Center with fractionated proton therapy as their 
first course of meningioma-directed radiation.  Table 1 lists patient and treatment characteristics.  
The median prescribed dose was 63 Gy (RBE) with a range of 54–68.4 Gy (RBE).  The median 
follow-up time after radiation therapy was 39 months (range 7–104 months), and all patients 
remain alive at last follow-up.  The 5-year estimate of local control was 71.1% (95% CI 49.6–
92.9%). One patient developed evidence of neuraxis spread and later distant metastases, with a 
5-year estimate of 5% (95% CI 0–14.6%) for neuraxis dissemination and 6.2% (95% CI 0–
18.2%) for extra-CNS metastases. 
 
In univariate analysis of this cohort, there was no statistically significant difference in local 
control by gender, age (continuous variable), use of radiation in the adjuvant setting or for 
7 
 
recurrent disease, number of prior surgeries, radiation induced tumors, or GTV at the time of 
radiation. Radiation dose was associated with local control. At five years, local control was 
maintained in 87.5% (95% CI 64.6–100%) who received doses greater than 60 Gy (RBE), 
compared to 50.0% (95% CI 15.3–84.7%) for those who received 60 Gy (RBE) or less (p=0.038) 
(Figure 1). 
 
Patterns of Failure, Salvage, Toxicity Analysis 
Five patients developed local tumor progression.  The median time to local tumor progression 
was 20 months from the completion of radiotherapy (range 13–39 months).  Four were isolated 
local failures, and all were within the radiation treatment field.  In the remaining patient, local 
tumor progression was accompanied by development of other foci of meningioma remote from 
the original site concerning for neuraxis spread and 10 months later by distant extra-CNS 
metastases.   All patients with local tumor progression have received salvage therapy of 
radiosurgery (n=3), surgery alone (n=1), and surgery followed by fractionated reirradiation 
(n=1). 
 
Acute toxicities related to radiation therapy were minimal, with grade 1-2 fatigue, and for 
patients with convexity and parasagittal meningiomas, temporary alopecia and mild radiation 
dermatitis.  One patient with a history of prior pituitary radiation was treated for a radiation-
induced sphenoid wing meningioma and developed grade 3 temporal lobe radiation necrosis that 
improved after treatment using pentoxifylline with vitamin E and hyperbaric oxygen. 
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Discussion 
Clinical outcomes for patients with grade 2 and 3 meningiomas are inferior to those with grade 1 
histology [12].  Table 2 summarizes results of radiotherapy from several studies.  No randomized 
clinical data are presently available to guide clinical management of these relatively uncommon 
histologies, although an open randomized trial seeks to establish whether there is a benefit to 
adjuvant radiotherapy after gross total resection of grade 2 meningiomas [23]. 
 
Results from a small phase I/II dose escalation trial for high-grade meningiomas were reported 
by colleagues at the Massachusetts General Hospital, suggesting promising long-term local 
control with dose escalated proton therapy [18].  A larger retrospective series from the same 
institution found an association between improved local tumor control and overall survival in 
patients treated with doses greater than 60 Gy [19].  These results were echoed in a report by 
colleagues at the Institut Curie, who similarly noted an association between doses greater than 60 
Gy and improved local control and overall survival [20].  Our own data also suggests a local 
control benefit for doses of greater than 60 Gy in patients with grade 2 meningioma receiving 
their initial meningioma-directed radiotherapy.  Because no deaths have yet been observed in this 
cohort, we cannot assess potential factors associated with overall survival. 
 
Not all series have seen an apparent benefit to treatment intensification for high-grade 
meningiomas [11].  A large multicenter retrospective review by the Rare Cancer Network on 119 
patients with high-grade meningiomas did not identify a dose response within the ranges utilized 
[24].  However, a recent systematic review of the literature summarizes that the majority of 
published studies on grade 2 and 3 meningiomas support an association between higher dose and 
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improved clinical outcomes [9].  The Radiation Therapy Oncology Group has completed a phase 
II non-randomized trial that proposed a risk stratification based on grade, extent of resection, and 
recurrence after prior surgery, utilizing 54 Gy for those assigned to an intermediate risk group, 
and 60 Gy for those deemed high risk.  The European Organisation for Research and Treatment 
of Cancer is also conducting a phase II non-randomized trial that utilizes 60 Gy for high-grade 
meningiomas after gross total resection and 70 Gy after subtotal resection.  Results from these 
trials should provide prospective data on higher dose treatment strategies to better guide clinical 
decision-making but will not directly address the question of optimal radiation dose. 
 
While our institutional approach has favored higher-dose radiotherapy for high-grade 
meningiomas, it was not always deemed appropriate, for example in two patients with radiation-
induced grade 2 meningiomas who were treated to 54 Gy (RBE) due to concern about 
cumulative radiation dose and tolerance of the adjacent optic apparatus.  Both of these patients 
fortunately maintain local control at last follow-up without visual complication. 
 
Most studies of high-grade meningiomas, including our own, are limited by their retrospective 
nature and all the usual patient selection and treatment biases which confound retrospective 
analysis.  Additionally, a limited number of patients precludes rigorous analysis of the many 
variables and confounding interactions of variables thought to be associated with outcomes.  
Longer-term follow-up is needed to capture late recurrences and toxicities after therapy.  Our 
data does not directly address what potential benefit proton therapy may offer over X-ray based 
modalities of therapy.  Others have demonstrated that proton therapy can achieve lower integral 
brain dose during treatment of intracranial targets [25].  These reductions may be meaningful in 
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patients with benign tumors at risk for late neurocognitive effects of brain radiation, but few 
clinical data are available.  Given the increasing data to suggest a benefit to higher dose for high-
grade meningiomas [9], it may be that proton therapy is preferential in targets where other 
treatment modalities are felt to have too great a risk in providing dose escalation[17]. 
 
Conclusions 
Fractionated proton therapy was associated with favorable tumor control rates for grade 2 
meningiomas.  Doses greater than 60 Gy (RBE) were associated with improved local control.  
Prospective studies are needed to define the optimal radiation dose for high-grade meningiomas. 
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Figure Legend 
Figure 1: Local tumor control outcomes stratified by radiation dose for patients receiving their 
initial meningioma-directed radiotherapy for grade 2 meningiomas. 
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Table 1: Patient and treatment characteristics 
 
Number of patients 22 
Age 
 Median (range) 42 years (14 – 75) 
Gender 
 Male 10 
 Female 12 
Tumor location 
 Parasagittal 7 
 Skull base 6  
 Convexity 5 
 Posterior fossa 3 
 Orbit 1 
Presumed radiation-induced 
 No 16 
 Yes 6 
Prior meningioma-directed radiation 0 
Prior surgical interventions 
 1 prior surgery 13 
 2 prior surgeries 7 
 3 prior surgeries 2 
Result of surgery prior to proton therapy 
 Gross total resection 11 
 Subtotal resection 11 
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Indication for proton therapy 
 Planned adjuvant therapy 12 
 Treatment for recurrence or progression 10 
Tumor identified at time of radiation planning 
 Yes 18 
 No 4 
GTV at time of proton therapy 
 Median (range) 8.1 cm3 (0–89.3) 
Dose of proton therapy 
 Median (range) 63 Gy (RBE) (54–68.4) 
 Dose ≤ 60 Gy (RBE) 8 
 Dose > 60 Gy (RBE) 14 
Number of proton treatment fields 
 Median (range) 5 (2 – 10) 
Number of proton fields treated daily 
 Median (range) 3 (1 – 4) 
WHO = World Health Organization, GTV = gross tumor volume, RBE = relative biological effectiveness. 
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Table 2: Results of radiotherapy for grade 2 and 3 meningiomas 
 
      Median Median Grade 2  Grade 3 
Institution Ref Years # pts Technique Dose f/u time 5yr LC  5yr LC 
MGH [19] 1973-1995 31 XRT or PBT 62.5 a 59 mo a 38%%  52% 
RCN [24] 1971-2005 119 XRT 54.6 a 49 mo 62% b  48% b 
Institut Curie [20] 1999-2006 25 XRT + PBT 64.2 48 mo 47% c 
U. Flor. [11] 1984-1999 36 HART + SRS 60 d + 12.5 41 mo 45% c 
Heidelberg [6] 1985-2004 45 XRT 59.4 43 mo 44.5% e  8.1% e 
PMH [12] 1966-1990 59 XRT 50 40 mo f 34%‡ g 
Wash. U. [14] 2000-2011 35 SRS 18 34.5 mo 30% e, h  0% 
Mayo [15] 1990-2008 50 SRS 15 38 mo 45% c 
U. Tokyo [16] 1991-2012 22 SRS 18 23.5 mo 16%  NA 
Present series  2005-2013 22 PBT 63 39 mo 71%  NA 
    
 
  
# pts = number of patients, Dose expressed in Gy, f/u = follow-up, mo = months, 5yr = 5-year, LC = local control, 
XRT = fractionated external beam photon therapy, PBT = proton beam therapy; SRS = stereotactic radiosurgery, 
HART = hyperfractionated accelerated radiation therapy, NA = not applicable, MGH = Massachusetts General 
Hospital, RCN = Rare Cancer Network, U. Flor. = University of Florida; PMH = Princess Margaret Hospital, 
Wash. U. = Washington University; U. Tokyo = University of Tokyo 
a mean value 
b Disease free survival 
c Results for grade 2 and 3 reported together 
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d Given in twice daily fractions of 1.5 Gy 
e Progression free survival 
f in patients remaining alive 
g crude control results 
h results at 3 years 
 
